|
|
|
|
| |
|
|
| Azevedo,Larissa Negromonte; Ximenes,Ricardo Arraes de Alencar; Monteiro,Polyana; Montarroyos,Ulisses Ramos; Miranda-Filho,Demócrito de Barros. |
| ABSTRACT Antiretroviral therapy (ART) has modified the outcome of patients with HIV infection, providing virological control and reducing mortality. However, there are several reasons as to why patients may discontinue their antiretroviral therapy, with adverse events being one of the main reasons reported in the literature. This is a case-control nested in a cohort of people living with HIV/AIDS, conducted to identify the incidence of ART modification due to adverse events and the associated factors, in two referral services in Recife, Brazil, between 2011 and 2014. Of the modifications occurred in the first year of ART, 25.7% were driven by adverse events. The median time elapsed between initiating ART and the first modification due to adverse events was... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Antiretroviral therapy; Zidovudine; Tenofovir; Efavirenz; Adverse events. |
| Ano: 2020 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702020000100065 |
| |
|
|
| Chen,Sihan; Ji,Rengbin; Shi,Xiaojun; Wang,Zhe; Zhu,Dedong. |
| The aim of our study was to assess the efficacy, safety, and prognostic factors of drug-eluting bead transarterial chemoembolization (DEB-TACE) in Chinese hepatocellular carcinoma (HCC) patients. Patients (n=102) diagnosed as primary HCC were consecutively enrolled in this retrospective cohort study. Treatment responses were assessed following the modified Response Evaluation Criteria in Solid Tumors. Progression-free survival (PFS) and overall survival (OS) were evaluated, and adverse events (AEs) as well as liver function-related laboratory indexes of all DEB-TACE records (N=131) were assessed. Complete response (CR) rate, objective response rate, and disease control rate were 51.0, 87.3, and 95.1%, respectively, at 1–3 months post DEB-TACE. The mean PFS... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hepatocellular carcinoma; Drug-eluting bead transarterial chemoembolization; China; Treatment response; Survival; Adverse events. |
| Ano: 2019 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2019001200608 |
| |
|
|
| Miotto,N.; Mendes,L.C.; Zanaga,L.P.; Goncales,E.S.L.; Lazarini,M.S.K.; Pedro,M.N.; Goncales Jr.,F.L.; Stucchi,R.S.B.; Vigani,A.G.. |
| The aim of this study was to determine risk factors for adverse events (AE)-related treatment discontinuation and severe anemia among patients with chronic hepatitis C virus (HCV) genotype 1 infection, treated with first-generation protease inhibitor (PI)-based therapy. We included all patients who initiated treatment with PI-based therapy at a Brazilian university hospital between November 2013 and December 2014. We prospectively collected data from medical records using standardized questionnaires and used Epi Info 6.0 for analysis. Severe anemia was defined as hemoglobin ≤8.5 mg/dL. We included 203 patients: 132 treated with telaprevir (TVR) and 71 treated with boceprevir (BOC). AE-related treatment discontinuation rate was 19.2% and anemia was the main... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hepatitis C treatment; Protease inhibitor; Anemia; Adverse events; Treatment interruption. |
| Ano: 2016 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016000700702 |
| |
|
| |
|
|
| Wiens,Astrid; Borba,Helena Hiemisch Lobo; Leonart,Letícia Paula; Tonin,Fernanda Stumpf; Steimbach,Laiza Maria; Araújo,Ariane Gonçalves Silva de; Piazza,Thais; Ferreira,Vinicius Lins; Pontarolo,Roberto. |
| The aim of this study was to evaluate interruption of treatment with biological drugs and tofacitinib due to adverse events in patients with rheumatoid arthritis. A systematic review was performed in the electronic databases MEDLINE, Cochrane, Scopus, CRD, IPA, Lilacs and Scielo. Case reports addressing interruption of treatment due to any adverse event related to abatacept (ABA), adalimumab (ADA), anakinra (ANA), certolizumab pegol (CER), etanercept (ETA), golimumab (GOL), infliximab (IFX), rituximab (RTX), secukinumab (SEC), tocilizumab (TCZ), tofacitinib (TOF) or ustekinumab (UST) in rheumatoid arthritis patients were evaluated. Baseline data, patient profile, previous and current treatments, cause of discontinuation and information on reintroduction of... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Rheumatoid arthritis; Biological drugs/treatment interruption; Tofacitinib; Adverse events. |
| Ano: 2018 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502018000400617 |
| |
|
|
|
